Beam Therapeutics (NASDAQ:BEAM – Get Rating) had its price target reduced by Royal Bank of Canada from $50.00 to $42.00 in a research note issued to investors on Thursday morning, The Fly reports. A number of other analysts have also commented on the company. Sanford C. Bernstein initiated coverage on Beam Therapeutics in a report […]
Beam Therapeutics (NASDAQ:BEAM – Get Rating) had its target price decreased by Barclays from $45.00 to $41.00 in a report released on Thursday morning, The Fly reports. Several other research analysts have also commented on the company. William Blair restated an outperform rating on shares of Beam Therapeutics in a research report on Wednesday, March […]
Beam Therapeutics Inc. (NASDAQ:BEAM – Get Rating) saw a large decline in short interest in April. As of April 15th, there was short interest totalling 12,870,000 shares, a decline of 5.4% from the March 31st total of 13,610,000 shares. Based on an average daily volume of 931,200 shares, the days-to-cover ratio is presently 13.8 days. […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Rating) have been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among […]